Alzheimer's hope as new drug appears to slow worsening of the disease

In the 18-month trial, people in the early stages of Alzheimer’s who received infusions of donanemab showed 35% less decline in thinking skills compared to those given a dummy drug, Eli Lilly announced in a press release.